An extra booster vaccination will improve efficacy of hepatitis A vaccination in travellers using immunosuppressive medication.
ID
Bron
Verkorte titel
Aandoening
hepatits A
vaccination
immunosuppression
Hepatitis A
vaccinatie
immuunsuppressie
Ondersteuning
fund=initiator=sponsor
fund=initiator=sponsor
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
- Antibody titres after booster vaccination.
Achtergrond van het onderzoek
Travelers who take immunosuppressive medication have a substantially increased risk of infection compared to the normal population and are thus candidates for preventive measures such as vaccination.
However, immunosuppression often alters the efficacy of vaccination. The antibody titres may be insufficient and even when sufficient may drop more quickly. When no protective antibodies are present after vaccination, the immunocompromised patient may become infected leading to spread of the disease among the population. Therefore, in case of insufficient antibody production the traveller needs passive immunisation with immunoglobulins, which is, however, expensive, has a limited protective duration and has the risk of transmission of blood borne diseases. In this study we propose to compare standard vaccination of hepatitis A with a vaccination regime that includes a booster vaccination in travellers taking immunosuppressive medication.
Doel van het onderzoek
An extra booster vaccination will improve efficacy of hepatitis A vaccination in travellers using immunosuppressive medication.
Onderzoeksopzet
preparation 3 months
inclusion 18 months
follow-up 24 months
Onderzoeksproduct en/of interventie
Boostervaccination of hepatitis A 2 weeks after first vacciantion.
Publiek
Department of Medical Microbiology <br>
PO Box 5800
A. Verbon
Maastricht 6202 AZ
The Netherlands
+31 (0)43 3876644
a.verbon@mumc.nl
Wetenschappelijk
Department of Medical Microbiology <br>
PO Box 5800
A. Verbon
Maastricht 6202 AZ
The Netherlands
+31 (0)43 3876644
a.verbon@mumc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. All consecutive patients > 18 years of age using immunosuppressive medication who come to the travel clinics and need vaccination with hepatitis A according to LCR guidelines.
- Immunosuppressive medication is defined as use of cyclosporine A, azathioprine, cyclophosphamide, methotrexate, TNF-รก blockers, prednisone use eqal to 10 mg/day or a cumulative dose of > 700 mg., tacrolimus, mycophenolate mofetil.
The study group will be compared with travelers > 18 years old that are immunocompetent.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Allergy to the advised vaccine or its components.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL677 |
| NTR-old | NTR1522 |
| Ander register | : |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |